Banderol Interactions Overview

Check For Interactions With Banderol

Banderol

Also known as
  • Otoba parvifolia
Banderol Banderol is a dietary supplement manufactured by Nutramedix. It contains Otoba parvifolia bark extract. Otoba parvifolia is a species of tree in the Myristicaceae family, which is native to the Amazonian region of South America. It is also known as the "Small-leaved Otoba". It is believed that the leaves and bark of the Otoba parvifolia tree have medicinal properties, such as anti-inflammatory properties that may help to reduce pain, swelling, and redness in the body. Additionally, the bark is thought to have antimicrobial properties, which may be effective against bacteria and fungi, including some that are resistant to antibiotics.
There are 173 drugs known to interact with Banderol

Banderol Uses

Banderol (otoba parvifolia), along with other Nutramedix products, such as Samento, are most often used for treatment-resistant Lyme disease.

Lyme disease is a tick-borne illness caused by the bacterium Borrelia burgdorferi, and the primary treatment for chronic Lyme disease is antibiotics, namely doxycycline. However, individuals often experience relapses or lingering symptoms after discontinuing treatment.

Some lab (i.e., in vitro) studies report that Banderol has antimicrobial effects on all forms of Borrelia burgdorferi, and could provide an effective therapeutic approach for treating Lyme disease, but more studies are certainly needed to confirm its effects.

Banderol is also sometimes used as an anti-inflammatory agent.

Pharmacokinetics

The pharmacokinetics of Banderol (Otoba parvifolia), including its absorption, distribution, metabolism, and excretion, have not been thoroughly studied in humans. Therefore, the current knowledge about the pharmacokinetics of Otoba parvifolia is limited.

Drug Interactions

There are very few scientific studies that have evaluated potential drug interactions with Banderol. Small, lab-based studies show that Banderol may inhibit the organic anion transporting polypeptides OATP1B1 and OATP1B3, which could affect the absorption of some drugs. Banderol does not appear to inhibit the metabolizing enzymes CYP1A2, CYP2B6, CYP2C19, or CYP3A4 or the drug efflux transporters P-gp and BCRP to a clinically significant degree.

Drugs that interact with Banderol

Return to the main supplement interaction checker page

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLCs